N/A N=488 Patch Study - Intervention for HIV Positive Smokers
Smoking Cessation · HIV
Primary: Rates of Smoking Cessation — 57; 46 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=66 Exploratory Study to Evaluate the Use of the RxSight Light Adjustable Lens (LAL) and the Light Delivery Device (LDD) to Improve Visual Outcomes
Aphakia · Cataract
Primary: Percent of Eyes With Uncorrected Distance Visual Acuity (UCDVA) of 20/20 or Better — 101 Eyes
Phase 4 N=99 Greater Occipital Nerve Block Versus Metoclopramide
Migraine
Primary: 0-10 Pain Score — 5.0; 6.1 units on a scale
Phase 2 N=51 Neoadjuvant Study of Sequential Eribulin Followed by FAC Compared to Sequential Paclitaxel Followed by FEC in Early Stage Breast Cancer Not Overexpressing HER-2
Breast Cancer
Primary: Pathologic Complete Response (pCR) — 7; 1 Participants
Phase 2 N=105 A Placebo-Controlled Study Using VP-102 in the Treatment of External Genital Warts
Condylomata Acuminata · Papillomavirus Infections · Skin Diseases, Viral
Primary: Proportion of Subjects Exhibiting Complete Clearance of All Treatable Warts at the Study Day 84 (End of Treatment) Visit. — 11; 1; 9; 0 Participants — p=0.0048
Phase 4 N=95 Connectivity Affecting the Antidepressant REsponse Study
Major Depressive Disorder
Primary: Number of Patients With Remission of Depression — 37; 13 Participants — p=0.0689
N/A N=44 Evaluation of a Full-Face Mask for the Treatment of Obstructive Sleep Apnea (OSA)
Obstructive Sleep Apnea
Primary: Trial Mask Comfort — 20; 16; 4; 1 Participants
Phase 2 N=80 Imetelstat Sodium in Treating Participants With Primary or Secondary Myelofibrosis
Primary Myelofibrosis · Secondary Myelofibrosis · Myeloid Malignancies
Primary: MF Participants: Percentage of Participants With Overall Response (OR) - (Clinical Improvement[CI] or Partial Remission[PR] or Complete Remission[CR]) Per International…
N/A N=130 A Study on the Safety of Hakim Programmable Shunt System
Hydrocephalus
Primary: Number of Participants With Non-infection Within One Year — 5 Participants
Phase 1 N=18 A Study of LY2140023 in Healthy Participants
Healthy Participants
Primary: Pharmacokinetics: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-inf]) of LY2140023 and LY404039 in Treatment Period 1 — 1160; 2620…
Phase 2 N=69 Panitumumab and Irinotecan as Third-Line Therapy in Treating Patients With Metastatic Colorectal Cancer
Colorectal Cancer
Primary: Objective Response Rate (ORR) During the Combination Therapy Phase — 29.2; 35.2; 46.3; 0 percentage of patients
Phase 1 N=16 Safety, Tolerability and Immunogenicity of ACI-24 Vaccine in Adults With Down Syndrome
Down Syndrome
Primary: Antibody Titer (Serum Anti-Aβ1-42 Free IgG) - Mean Absolute Value — 632.3; 335.4; 162.8; 751.5 AU/mL (AU: Arbitrary Unit)
Phase 1 N=27 A Study of LY2140023 in Healthy Participants
Healthy Volunteer Study
Primary: Pharmacokinetics: Maximum Observed Plasma Concentration (Cmax) of LY2140023 — 251; 171 nanograms per milliliter (ng/mL)
Phase 1 N=35 A Study of LY2140023 in Healthy Males and Females
Healthy Volunteers
Primary: Pharmacokinetics: Maximum Concentration (Cmax) of LY2140023 — 277; 290; 304; 284 nanograms per milliliter (ng/mL)
Phase 2 N=140 Metabolic Resuscitation Using Ascorbic Acid, Thiamine, and Glucocorticoids in Sepsis.
Sepsis, Severe · Septic Shock
Primary: Time to Vasopressor Independence (Hours) — 27; 53 hours — p=<0.001